SCHEMBL4695940

SCHEMBL4695940

O=C(O)C(O)=CC(=O)c1ccn(Cc2ccccc2F)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.50
ALDH1A1 P00352 6/20 0.50
MEN1 O00255 5/20 0.50
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
ATM Q13315 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
MAPT P10636 3/20 0.39
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
STAT3 P40763 2/20 0.38
LMNA P02545 2/20 0.38
HPGD P15428 1/20 0.38
TP53 P04637 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPK1 P28482 1/20 0.38
PKM P14618 1/20 0.37
PTGER1 P34995 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4671228 0.83 HDAC1 (0.50) KMT2AALDH1A1MEN1NPC1RAB9A
SCHEMBL17611000 0.83 KMT2A (0.59) KMT2AALDH1A1MEN1NPC1RAB9A
SCHEMBL4678097 0.80 NPC1 (0.45) ALDH1A1NPC1RAB9AL3MBTL1MAPT
SCHEMBL4676305 0.79 ALDH1A1 (0.42) KMT2AALDH1A1MEN1NPC1RAB9A
SCHEMBL4670920 0.79 ALDH1A1 (0.42) KMT2AALDH1A1MEN1NPC1RAB9A
SCHEMBL4675432 0.78 L3MBTL1 (0.52) KMT2AALDH1A1NPC1RAB9AL3MBTL1
SCHEMBL4675177 0.78 ALDH1A1 (0.41) KMT2AALDH1A1MEN1L3MBTL1MAPT
SCHEMBL4671192 0.77 ALDH1A1 (0.54) KMT2AALDH1A1MEN1RAB9AATM
SCHEMBL4676243 0.75 HDAC1 (0.40) KMT2AALDH1A1MEN1NPC1RAB9A
SCHEMBL4673761 0.74 HDAC1 (0.39) KMT2AALDH1A1MEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 KMT2A 597/4885ALDH1A1 980/4885MEN1 4663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.